Exploring Statera Biopharma, Inc. (STAB) Investor Profile: Who’s Buying and Why?

You are looking at Statera Biopharma, Inc. (STAB), a stock trading around $0.0001 per share, and you have to wonder: who is buying this, and why? Honestly, the investor profile for this clinical-stage biopharma tells a story of extreme risk tolerance and a massive disconnect between its valuation and its burn rate. The company's market capitalization is a tiny $7.142K as of November 2025, yet its trailing twelve-month net loss is a staggering -$91.83 million, a clear sign that the few buyers are betting on a massive, binary event-a clinical trial success or a strategic pivot-not fundamentals. Institutional money is mostly absent, which is no surprise, but the 5.5% insider ownership is a key data point; it shows management still has skin in the game, but it's a small fraction compared to the 14.0% average for pharmaceutical preparations companies. So, is this a deep-value play for a breakthrough immunotherapy, or just a lottery ticket on a highly volatile asset with a beta of 0.33, which is surprisingly less volatile than the S&P 500? Let's break down the holders and the logic behind their positions.

Who Invests in Statera Biopharma, Inc. (STAB) and Why?

The investor profile for Statera Biopharma, Inc. (STAB) is not what you see in a large-cap, blue-chip stock. The company's composition is dominated by retail speculation and a tight circle of insiders, not the typical institutional heavyweights like BlackRock or Vanguard. This setup tells you exactly what kind of game you are playing here: a high-risk, binary-outcome bet.

Based on recent filings, institutional ownership is remarkably low, with a reported total of only around 1,000 shares held by major institutions, which is practically zero in the grand scheme of things. This suggests that large money managers, who typically look for liquidity and established revenue, are largely absent. Instead, the general public-the retail investor-holds the vast majority of the float, a common characteristic of micro-cap and over-the-counter (OTC) stocks like STAB.

Insiders, however, maintain a notable position, holding about 5.5% of the shares outstanding as of the end of 2025. This level of insider skin-in-the-game is an important signal, but it's not enough to control the stock's direction alone. The real action is with the individual investors chasing the 'moonshot.'

Investment Motivations: Chasing the Binary Event

Investors are drawn to Statera Biopharma, Inc. for one primary reason: the potential for explosive growth (a binary event) tied to its clinical-stage pipeline. This is a classic biotech investment thesis. The company's focus is on developing novel immunotherapies for conditions like autoimmune diseases and cancers. The investment is not about current earnings; it's about future drug approval.

To be clear, the company is not profitable. For the last twelve months, Statera Biopharma reported a net loss of approximately -$91.83 million on revenue of only $3.69 million. This completely eliminates value investors and those seeking dividend income, as the dividend yield is N/A. You are buying a lottery ticket on the science. If a key clinical trial succeeds, the stock could see a massive percentage jump from its current price of around $0.0001 per share.

The motivation is pure speculation on a turnaround, not a stable return. Here's the quick math: with a market capitalization of only about $14,517 as of November 2025, even a small positive development could lead to a multi-bagger return for a retail investor. This is why the stock is a magnet for risk-tolerant speculators. You can read more about the long-term vision in the Mission Statement, Vision, & Core Values of Statera Biopharma, Inc. (STAB).

Investment Strategies: Short-Term Trading and Hype

Given the low price, low volume, and clinical-stage status, the dominant strategy is short-term, speculative trading. This is not a long-term holding for most people. The stock's price movements are often driven by sentiment and media hype, a phenomenon known as the fear of missing out (FOMO), rather than fundamental analysis.

The current technical picture supports this short-term view. As of late November 2025, the stock is in a wide and falling trend, with the Relative Strength Index (RSI) below 20, which is a technical indicator suggesting the stock is significantly oversold. This oversold condition is exactly what attracts short-term traders looking for a quick, mean-reversion bounce.

The strategies at play are:

• Speculative Swing Trading: Buying on extreme dips, like the current oversold condition, to capture a rapid percentage gain.
• Hype-Driven Arbitrage: Trading on news headlines or social media trends that momentarily boost the stock price, then selling quickly.
• Long-Shot Value Investing (Deep Value): A smaller group of investors may hold for the long term, betting that the current market cap of $14,517 is defintely too low for a company with valuable immunotherapy intellectual property, even if it is pre-revenue.

The overall market sentiment is currently Bearish. Still, the extreme price volatility and tiny market cap make it a playground for those who treat it more like a trade than an investment. The low institutional presence means there is less sophisticated money to stabilize or anchor the price, making it highly susceptible to these retail-driven trading strategies.

Institutional Ownership and Major Shareholders of Statera Biopharma, Inc. (STAB)

If you're looking for a roster of BlackRock-sized funds loading up on Statera Biopharma, Inc. (STAB) stock, the hard truth is you won't find one. The most critical takeaway for any investor right now is the near-total absence of significant institutional ownership, which is a direct consequence of the company's delisting from Nasdaq in January 2023.

For a clinical-stage biopharma company, this lack of institutional backing is a massive signal. While the average institutional ownership for the broader 'Pharmaceutical preparations' sector sits around 39.4%, Statera Biopharma, Inc. has virtually none. This means the stock is almost entirely in the hands of retail investors, insiders, and very small funds.

Top Institutional Investors: The Near-Zero Reality

The institutional investor profile for Statera Biopharma, Inc. is defined by its scarcity. As of the most recent data near the 2025 fiscal year, the company, which trades on the OTC Pink Open Market (OTCPK:STAB), reports a negligible institutional footprint. For example, in the second quarter of 2024, only 1 hedge fund or large institution was reported to have an investment, totaling a mere $1 in invested capital.

To be clear, this is not a rounding error. It means the company does not meet the criteria for most major money managers-those who typically file a 13F with the SEC-to hold a position. Fintel data, for instance, shows 0 institutional owners who have filed the required 13D/G or 13F forms. This is the kind of data point that forces a decision: either you see an overlooked deep-value opportunity, or you see a stock that is too illiquid and high-risk for professional capital.

• STAB Institutional Holders: 1 (as of 2024 Q2)
• Total Institutional Capital: $1 (as of 2024 Q2)
• Industry Institutional Average: 39.4% of shares outstanding

Changes in Ownership: A Flatline After Delisting

Institutional buying and selling trends are usually a key indicator of smart money sentiment, but for Statera Biopharma, Inc., the trend is a flatline. The company's common stock was suspended from trading on Nasdaq and delisted in January 2023, largely due to not meeting continued listing requirements like the $1.00 bid price. This move immediately shutters the door to most mutual funds, pension funds, and ETFs, whose charters prevent them from holding over-the-counter (OTC) stocks.

So, there hasn't been a significant change in institutional ownership recently because the stock is off-limits to most large players. The number of institutional holders and the capital invested remained stable at 1 holder and $1 from 2024 Q2 into 2025. This isn't a sign of conviction; it's a sign of dormancy. Any movement you see in the stock price is driven by retail sentiment, not by the heavy, stabilizing hand of institutional money.

Impact of Institutional Investors: High Risk, Low Liquidity

The role of institutional investors in a stock is to provide liquidity and, often, a degree of price stability. When they are absent, as is the case with Statera Biopharma, Inc., you get a very different risk profile. The stock's market capitalization is small-around $4.98 million-which means even a small trade can move the price dramatically.

This low institutional presence translates directly into three near-term risks for you:

• Extreme Volatility: The stock's beta (a measure of volatility) is low at 0.33, but this is misleading; it's less volatile than the S&P 500 because it barely trades. When a trade does happen, the price can swing wildly.
• Liquidity Risk: Selling a large block of shares can be defintely difficult without crashing the price, as there are no large institutional buyers waiting to absorb the volume.
• Limited Oversight: Institutional investors often demand better corporate governance and financial transparency. Without them, management faces less external pressure, which is a key factor to consider when reviewing the company's financial health. You can see a deeper dive on the underlying numbers here: Breaking Down Statera Biopharma, Inc. (STAB) Financial Health: Key Insights for Investors.

The bottom line is that your investment thesis here must be entirely based on the company's clinical pipeline-its proprietary platform for immunotherapies targeting autoimmune and cancer indications-and not on a belief that a major fund is about to step in and validate the price. The market is telling you this is a high-conviction, high-risk bet on the science alone.

Key Investors and Their Impact on Statera Biopharma, Inc. (STAB)

You're looking for the big money behind Statera Biopharma, Inc. (STAB), and honestly, the landscape is almost empty of the institutional giants you might expect. The key takeaway is that major institutional investment in STAB is virtually non-existent, meaning the stock's movements are driven by retail traders and internal actions, not BlackRock-level portfolio shifts.

As of the 2025 fiscal year data, the institutional ownership for Statera Biopharma, Inc. is reported as 0 institutional owners and shareholders filing 13D/G or 13F forms with the SEC. For perspective, most pharmaceutical companies see around 39.4% of their shares held by institutions, which are those large money managers, endowments, and hedge funds. This stark difference tells you that the stock is currently a micro-cap speculation play, not a core holding for major funds.

The Real Players: Convertible Note Holders and Insiders

When you don't have institutional equity investors, you look to the debt holders and insiders for influence. The most notable financial players in recent years have been Silverback Capital and AVOF, who were involved in a significant debt restructuring. In October 2022, Statera Biopharma, Inc. reached an agreement with Silverback Capital to acquire $400,000 of a larger $15 million promissory note, converting it into an amended convertible note due in May 2024. This kind of arrangement is crucial for a company struggling with compliance and cash flow, as it provides a lifeline, but also gives the note holders substantial leverage over the company's financial decisions.

Here's the quick math on who owns the company right now:

• Insider Ownership: 5.5% of shares, as of November 2025.
• Institutional Ownership: 0 major 13F filers.
• Retail/Other Ownership: The remaining 94.5% of the float.

The 5.5% insider ownership is a relatively small stake compared to the industry average of 14.0%, but in the absence of institutional oversight, this group-executives and directors-holds disproportionate control over the company's direction. Their influence is paramount, especially in strategic decisions like mergers or asset sales.

Recent Moves and the True Investor Influence

The real influence on Statera Biopharma, Inc.'s stock and operational strategy in the near-term comes from corporate actions and regulatory compliance efforts, not from a fund manager buying a large block of shares. For example, in February 2025, Tivic Health Systems acquired exclusive worldwide rights to a Phase III TLR5 Agonist from Statera Biopharma, Inc., Entolimod. This is a defintely a value-unlocking event, essentially monetizing an asset to shore up the balance sheet.

What this absence of institutional money hides is the extreme risk. With the stock trading at $0.0001 per share as of November 20, 2025, and a history of non-compliance issues with Nasdaq, the company is in a precarious position. The influence of the few known financial parties, like the note holders, is less about maximizing long-term returns and more about ensuring the company can meet its debt obligations or pursue a strategic transaction, like the previously discussed merger with Worksite Labs, Inc. in 2023, which aimed to enhance shareholder value.

For a deeper dive into the company's background and strategic shifts, you should review Statera Biopharma, Inc. (STAB): History, Ownership, Mission, How It Works & Makes Money. The current investment profile is one of high-risk, high-speculation, where a single corporate announcement can move the price, given the low trading volume and tiny share price. The lack of a major institutional base means there's no anchor to provide stability or demand for the stock.

Your next step should be to monitor SEC filings for any new convertible debt agreements or insider transactions, as those are the only moves that truly matter for this stock right now.

Market Impact and Investor Sentiment

You're looking at Statera Biopharma, Inc. (STAB) and asking the right question: who is buying this stock and why? Honestly, the current picture is one of extreme caution, bordering on outright avoidance from institutional players. The market sentiment for Statera Biopharma, Inc. is defintely bearish right now, which is a direct takeaway from the technical analysis.

As of November 2025, the technical indicators are overwhelmingly negative, with 0 signals pointing toward a bullish trend and 26 signaling a bearish outlook. This isn't a mixed signal; it's a clear consensus among the algorithms tracking price action. Furthermore, the Fear & Greed Index, a common gauge of market emotion, sits at 39, firmly in the Fear territory. This means investors are generally risk-averse regarding this specific stock. Insider sentiment is a bit more muted, registering as Neutral, primarily because recent insider trading has been of low impact, showing no strong, unified buying or selling consensus.

Recent Market Reactions and Risk Profile

The stock's price action reflects this deep-seated fear and bearish sentiment. As of November 20, 2025, the share price for Statera Biopharma, Inc. was at a mere $0.0001. This price point, combined with the company's tiny market capitalization of approximately $7.142K as of the same date, places it in the micro-cap, high-risk category. The stock is currently in a very wide and falling trend, and its daily volatility, while sometimes minimal in absolute dollars (like the 0% movement on Nov 20, 2025), is considered very high risk due to the large prediction interval.

Here's the quick math on the risk: the stock's beta is 0.33, suggesting it's technically less volatile than the S&P 500. But what this estimate hides is the extreme price level and the fundamental risk of an Over-The-Counter (OTC) stock that has been subject to Nasdaq delisting notices in the past. If you want to dive deeper into the core financial health that drives this risk, you should read Breaking Down Statera Biopharma, Inc. (STAB) Financial Health: Key Insights for Investors.

• Stock price is $0.0001 (Nov 20, 2025).
• Market Cap is roughly $7.142K (Nov 20, 2025).
• Sentiment is Bearish (0 bullish, 26 bearish signals).

Analyst and Institutional Investor Perspectives

The lack of significant institutional buying tells you everything about the professional view on Statera Biopharma, Inc.'s future. Institutional ownership is incredibly thin. While the 'Pharmaceutical preparations' sector typically sees institutional investors hold 39.4% of shares, Statera Biopharma, Inc. has a far lower percentage. Our data shows only 1 institutional holder with a position of 1,000 shares as of the end of 2024. The company is not owned by hedge funds, and insiders hold only 5.5% of the shares, which is also below the sector average of 13.9%.

The analyst community has essentially stepped away. Statera Biopharma, Inc. is covered by 0 analysts, meaning there is no consensus estimate for future earnings or revenue. This lack of coverage is rare and signals a high degree of uncertainty or a market view that the stock is too small or too volatile to warrant the resources of a major research firm. No one is providing a target price, so you are truly on your own here.

To give you the necessary context for this investor profile, here are the key financial figures from the 2025 fiscal year data (Trailing Twelve Months, or TTM, data as of August 2025):

The people who are buying now are mostly retail investors or those betting on an extreme, high-risk turnaround, perhaps based on a future clinical trial success or a strategic merger, like the one previously explored with Worksite Labs, Inc. The numbers show the company is facing significant headwinds, with a negative Return on Equity of over -286%. Your action item should be clear: treat this as a highly speculative bet, not a fundamental investment.